Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with 80% YoY growth, promising product pipeline, and strategic partnerships. The Q&A section highlights management's confidence in scalability and future launches, despite some lack of specificity. The guidance reflects robust revenue projections, and the absence of negative financial surprises suggests a positive market reaction.
Key Financial Performance
Royalty Revenues Increased 43% year-over-year to $241 million, driven by the commercial ENHANZE portfolio and adoption of subcutaneous drug delivery.
Total Revenue Increased 42% year-over-year to $377 million, reflecting the strength of the commercial royalty portfolio.
Adjusted EBITDA Increased to $230 million, representing a greater than 40% increase year-over-year, driven by revenue growth.
Non-GAAP Earnings Per Share Increased to $1.60, representing a greater than 40% increase year-over-year, attributed to strong financial performance.
DARZALEX Global Sales Generated approximately $4 billion in global sales in Q1 2026, representing nearly 18% operational growth. This translated into $129 million in royalty revenue for Halozyme, a 26% year-over-year increase, driven by sustained double-digit growth and new indication approvals.
VYVGART Global Sales Generated approximately $1.3 billion in global sales in Q1 2026, representing nearly 63% growth. Royalty revenue increased 119% to $46.3 million, driven by growing demand, uptake, and the introduction of a prefilled syringe for subcutaneous administration.
PHESGO Global Sales Increased 27% year-over-year to CHF 686 million (approximately USD 877 million), generating $30.2 million in royalty revenue for Halozyme, a 25% year-over-year growth, driven by strong adoption and durable revenue tail.
OCREVUS ZUNOVO Subcutaneous Patients Approximately 24,000 patients globally receiving subcutaneous OCREVUS, an increase of roughly 7,000 patients versus the prior quarter, driven by reduced infusion burden and expanded access to multiple sclerosis care settings.
RYBREVANT Global Sales Generated $257 million in Q1 2026, representing 80% year-over-year growth, driven by launch uptake and share gains across regions, supported by the subcutaneous formulation with ENHANZE.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ENHANZE launch products: Strong performance with DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO driving revenue growth. Royalty revenues increased 43% year-over-year to $241 million. Total revenue for the quarter increased 42% year-over-year to $377 million.
New ENHANZE pipeline products: Up to 13 additional ENHANZE partner products projected for launch in the 2029+ timeframe. Two ENHANZE partners initiated Phase I studies in Q1 2026.
Hypercon: First two Phase I clinical starts projected for 2027, with launches in 2030-2031. Hypercon projected to achieve $1 billion in royalty revenues by mid-2030s.
Surf Bio: Investments planned to drive future growth.
New collaborations and licensing agreements: Three new agreements signed in 2026, including partnerships with GSK, Vertex Pharmaceuticals, and Oruka. These agreements expand ENHANZE and Hypercon applications into oncology and inflammatory diseases.
Global market expansion: DARZALEX subcutaneous achieved $4 billion in global sales in Q1 2026, with 18% operational growth. VYVGART Hytrulo generated $1.3 billion in global sales, growing 63% year-over-year.
Revenue growth: Total revenue increased 42% year-over-year to $377 million. Royalty revenues grew 43% year-over-year to $241 million.
Capital allocation: Announced $1 billion share buyback authorization, with $400 million planned for 2026. Plans to retire 2027 and 2028 notes at maturity.
Long-term revenue drivers: Four key drivers identified: 10 approved ENHANZE products, 13 additional ENHANZE launches, 2 Hypercon launches, and new collaborations.
Focus on durable growth: Investments in ENHANZE, Hypercon, and Surf Bio to sustain long-term value creation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces potential challenges in obtaining regulatory approvals for new product launches and label expansions, which could impact the timeline and success of its pipeline.
Supply Chain and Manufacturing Risks: Investments in manufacturing capacity for Hypercon products and potential delays in finalizing clinical supply manufacturing could disrupt timelines for product launches in 2030 and 2031.
Market Competition: The company operates in highly competitive markets, including oncology and autoimmune diseases, where competitors may introduce alternative therapies that could impact market share and revenue growth.
Strategic Execution Risks: The success of the company's 2029+ revenue strategy depends on the execution of multiple drivers, including the launch of up to 13 ENHANZE products and 2 Hypercon products, as well as securing new collaboration and licensing agreements.
Economic and Financial Risks: The company plans significant capital allocation, including a $1 billion share buyback and investments in new technologies, which could strain financial resources if revenue projections are not met.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Guidance: Halozyme reaffirms its 2026 financial guidance, projecting total revenue of $1.71 billion to $1.81 billion, representing year-over-year growth of 22% to 30%. Royalty revenues are expected to range from $1.13 billion to $1.17 billion, reflecting 30% to 35% growth. Adjusted EBITDA is projected between $1.125 billion and $1.205 billion, with non-GAAP diluted EPS of $7.75 to $8.25.
2026-2028 Financial Guidance: The company projects ENHANZE royalties to exceed $1 billion in 2026, representing 30% to 35% growth over 2025. Adjusted EBITDA margin is expected to grow from greater than 65% to approximately 70% during this period. Halozyme plans to deploy capital in four key areas: organic investments, a $1 billion share buyback authorization (with $400 million in 2026), deleveraging by retiring 2027 and 2028 notes, and evaluating drug delivery M&A opportunities.
2029+ Revenue Drivers: Revenue in and post-2029 will be driven by four key sources: continued performance of 10 current ENHANZE launch products, up to 13 new launches from the ENHANZE pipeline by 2029, two Hypercon product launches in 2030-2031, and additional launches from new nominations and collaborations. The company projects 66% of the total projected royalties from the 10 approved products to be realized between 2026 and 2032.
Hypercon and Surf Bio Investments: Halozyme plans to invest in manufacturing capacity for Hypercon, aiming for end-to-end services. The first two Phase I clinical starts for Hypercon are projected in the first half of 2027, with launches expected in 2030-2031. Hypercon is projected to achieve approximately $1 billion in royalty revenues by the mid-2030s.
New Collaboration and Licensing Agreements: In 2026, Halozyme has already signed three new collaboration and licensing agreements, including partnerships with GSK, Vertex Pharmaceuticals, and Oruka. These agreements include multiple targets with multi-billion dollar sales potential, expanding the ENHANZE and Hypercon pipelines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Authorization: A new $1 billion share buyback authorization was announced, with an expectation of buying back at least $400 million of shares in 2026. The company projects a 3% annual share buyback yield.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the biggest products expected in the ENHANZE portfolio post-2029, and when will they peak?
A:Helen Torley mentioned that 66% of the revenue from the current 10 launched products will come between 2026 and 2032. Products like OCREVUS, RYBREVANT, VYVGART, and DARZALEX are expected to contribute substantially. However, individual breakdowns were not provided.
Q:How many Hypercon transactions or discussions were ongoing before the acquisition, and how many are new?
A:Helen Torley stated that one discussion was ongoing before the acquisition, one was new, and multiple other groups are involved in early feasibility testing or development testing.
Q:What is the status of the two Phase I clinical starts with Hypercon assets, and what is left to finish?
A:The two Phase I clinical starts are expected in the first half of next year. Clinical manufacturing is currently being worked on, and investments in manufacturing capacity are ongoing to support these starts.
Q:What is the timeline for the 13 additional ENHANZE launches post-2029?
A:The 13 launches are expected between 2029 and 2032, with the latest approvals anticipated by 2031-2032. It typically takes 4-5 years for ENHANZE products to get approval from Phase I clinical testing.
Q:How scalable is the Hypercon technology, and what work has been done to ensure its scalability?
A:Helen Torley expressed confidence in the scalability of Hypercon technology. Collaborations with Thermo Fisher Patheon for engineering and clinical batches are ongoing, and investments in manufacturing capacity are being made to support clinical and commercial use.
Q:What are the financial milestones included in the 2026 guidance, and how does the buyback impact EPS guidance?
A:All predictable milestones, including new deal milestones, are included in the 2026 guidance. The EPS guidance does not include any potential impact from share repurchases.
Q:What are the differences in manufacturing scale-up between Hypercon and Surf Bio?
A:Surf Bio is 18-24 months earlier in development than Hypercon. Surf Bio relies on spray drying, a common manufacturing process, while Hypercon uses a novel dehydration process to create microparticles. Both are progressing in their respective stages.
Q:What royalty rates and IP positions are expected for the 13 ENHANZE products launching post-2029?
A:Royalty rates are expected to be in the mid-single-digit range, with some newer contracts starting at single-digit royalties and escalating. The IP position is strong due to co-formulation patents, which extend royalty terms beyond the base composition of matter patents expiring in 2029.
Q:What is the competitive landscape for hyaluronidase technologies, and how does ENHANZE compare?
A:Helen Torley emphasized ENHANZE's leadership with over 1.3 million patients treated and its expertise in rapid clinical development. She noted that companies often approach Halozyme first due to its gold-standard reputation, despite competitors like Alteogen and Sanofi.
Q:What are the development timelines for Hypercon products after entering Phase I?
A:Development timelines are expected to be 3-4 years from Phase I to approval, based on comparability studies and FDA's comfort with existing safety data.
Q:What is driving early success in Hypercon partnerships?
A:The ability to create competitive target product profiles, such as extended dosing and patient self-administration, is resonating with partners. Hypercon's fit with market trends in areas like inflammation and immunology is also a key factor.
Q:Did Vertex or Oruka conduct early feasibility testing before signing Hypercon deals?
A:Helen Torley did not disclose specific details about individual collaborations, citing partner confidentiality.
Q:What are the economics of new licensing deals for Hypercon and ENHANZE?
A:Hypercon deals include upfront milestones, development and sales milestones, and mid-single-digit royalties. ENHANZE deals also have the potential for mid-single-digit royalties, with some newer contracts starting at single-digit royalties and escalating.
Q:What is the status of ADC and nucleic acid partnerships?
A:ADC discussions are product-specific and driven by the potential to optimize target product profiles. Nucleic acid discussions are occurring in parallel, with compelling nonclinical data being shared with several companies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the individual breakdown of ENHANZE product contributions post-2029, the exact timeline for Hypercon deals to enter the clinic, and whether Vertex or Oruka conducted early feasibility testing before signing Hypercon deals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Argenx Phase
Bio share
CLAs
DARZALEX PHESGO
Dr Torley
ENHANZE Surf
ENHANZE agreement
ENHANZE collaboration
ENHANZE launch
ENHANZE partner
ENHANZE product
GSK
Interim Chief
OCREVUS
OPDIVO TECENTRIQ
ORKA
RYBREVANT
Surf Bio
Vertex
agreement ENHANZE
agreement collaboration
capital
collaboration licensing
contribution ENHANZE
driver ENHANZE
driver wave
frame ENHANZE
frame driver
gravis
launch frame
licensing agreement
momentum
partner target
period
potential
product launch
royalty Halozyme
target ENHANZE
term value
wave launch
HALO Transcript
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call indicates strong financial performance with 80% YoY growth, promising product pipeline, and strategic partnerships. The Q&A section highlights management's confidence in scalability and future launches, despite some lack of specificity. The guidance reflects robust revenue projections, and the absence of negative financial surprises suggests a positive market reaction.
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-11
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
HALO Slides
HALO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
